Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Inflammatory Agents

Antiemetics

Gastrointestinal Agents

Dermatologic Agents

Reproductive Control Agents

Neuroprotective Agents

Micronutrients

Hematinics

Vitamins

Cytarabine

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Dexamethasone

Sargramostim

Methotrexate

Rituximab

Vincristine

Prednisolone

Lenograstim

Dexamethasone acetate

BB 1101

Pegaspargase

Methylprednisolone

Asparaginase

Methylprednisolone Acetate

Methylprednisolone Hemisuccinate

Prednisolone acetate

Prednisolone hemisuccinate

Prednisolone phosphate

Mesna

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Antineoplastic Agents, Immunological

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Antimetabolites

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Antiviral Agents

Tubulin Modulators

Antimitotic Agents

Protective Agents

Folinic Acid

Folate

Vitamin B9

Rituximab 375 mg/m\^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m\^2 IV, Doxorubicin 50 mg/m\^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m\^2 IV followed by 800 mg/m\^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m\^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day IV, Pegylated asparaginase 2000 International units/m\^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.

Cyclophosphamide (CTX)

12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7

200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8

Methotrexate (MTX)

100 mg intrathecal for Courses 1,3,5,7

3 gm/m2 by vein for Courses 2,4,6,8

G-CSF

Pegylated asparaginase

6 mg (flat dose) within 72 hrs after completion of chemotherapy

Pegfilgrastim

Solumedrol

Susan O'Brien, M.D.

The goal of this clinical research study is to learn if intensive chemotherapy (with monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed by monthly maintenance chemotherapy for 2 ½ years can improve or cure acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.

The modified hyper-CVAD regimen is a combination of chemotherapy drugs including cyclophosphamide, vincristine, Adriamycin, dexamethasone and pegylated asparaginase given together for one "course" of treatment. This alternates with a course or combination of the chemotherapy drugs methotrexate, cytarabine (ara-C), and pegylated asparaginase. Rituximab is a protein (monoclonal antibody) that attaches to the surface of the leukemia or lymphoma cells, which have a marker, called "CD20".

Before treatment starts, participants will have a complete physical exam, including blood (about 8 teaspoons) tests. A chest X-ray may be taken. CT scans may be taken if needed. A bone marrow sample will be taken through a large needle in the hipbone. Women able to have children must have a negative blood pregnancy test. An ECG (tracing of the heart) and a cardiac scan or echocardiogram may be taken to check the heart function.

Participants will receive these 2 kinds of intensive chemotherapy courses for a total of 8 courses as long as they are able to tolerate them. Chemotherapy courses will be given through a large vein by a central venous catheter (a plastic tube usually placed under the collarbone) or a long-line catheter (a plastic tube usually placed in the upper arm).

During treatment, participants will have a physical exam and undergo blood tests (about 1 tablespoon each) at least twice a week. After the first course of chemotherapy, the tests done before treatment will be repeated to check for response. In patients with acute lymphoblastic leukemia or lymphoblastic lymphoma with marrow disease, a bone marrow sample will be repeated about 2 and 3 weeks from the beginning of treatment to check the response.

Course 1 (odd courses) will start by giving rituximab by vein over 6 hours on Day 1 and Day 11 for patients whose leukemia or lymphoma expresses CD20. Participants will receive the drugs acetaminophen (Tylenol) and diphenhydramine hydrochloride (Benadryl) 30-60 minutes before each dose of rituximab. This will be done to lessen the risk of fever, chills, and allergic reactions. Usually, the first dose of rituximab requires about 6 to 8 hours to complete. If side effects do occur during the infusion, participants will be observed for an additional 2 hours after the rituximab is given. Then, the cyclophosphamide will be given as described below.

Other participants who do not have the CD20 marker will start Course 1 with cyclophosphamide given by vein over 2-3 hours every 12 hours. This will be given for 6 doses over 3 days (Days 1,2, and 3). Pegylated asparaginase will be given by vein over 30 minutes on Day 1. Adriamycin will be given by vein over 24 hours on Day 4. Vincristine will be given by vein over 15 to 30 minutes on Days 1 and 11. Dexamethasone (a steroid) will be given by mouth or by vein on Days 1 to 4 and 11 to 14.

Pegfilgrastim (a growth colony stimulating factor) will be given after each course of chemotherapy is finished. It is given to help with rapid recovery of the white blood cells in the normal marrow. Pegfilgrastim will be injected under the skin within 72 hours of completion of each cycle of chemotherapy. Filgrastim, a shorter active form of pegfilgrastim may be used instead or added later if needed.

Treatment to protect the brain will be given inside the spinal using lumbar punctures (spinal taps) with chemotherapy, including methotrexate around day 2 and cytarabine (ara-C) about day 7 of the course. This is done to decrease the risk that the leukemia or lymphoma will develop there. If there is leukemia or lymphoma in the spinal fluid at the time of the first spinal tap, then the treatments will be given more frequently.

For patients aged 60 years or older, this first course of chemotherapy will be given in a protective isolation room to decrease the risk of infection(s).

During Course 2, participants whose leukemia expresses CD20 will receive rituximab by infusion over 4 hours on Days 1 and 8. Other participants who do not have CD20 on the leukemia cells will start with methotrexate by vein over 24 hours on Day 1. Cytarabine (ara-C) will be given by vein over 2 hours every 12 hours for 4 doses (Days 2 and 3). Vincristine will be given by vein over 15 to 30 minutes on Days 1 and 8. Pegylated asparaginase will be given by vein over 30 minutes on Day 4 or 5 after the methotrexate has cleared (as checked by blood tests).

Citrovorum factor (leucovorin), an antidote for side effects of methotrexate, will be given by vein or by mouth for 2-3 days (Day 2 and on). Pegfilgrastim will be given as in Course 1 (24-72 hours after the chemotherapy is finished). The treatment to protect the brain inside the spinal fluid will be given as in Course 1 on Days 2 and 7.

The rest of the chemotherapy will switch between hyper-CVAD and pegylated asparaginase (Courses 3, 5, and 7) and methotrexate,cytarabine (ara-C), vincristine, and pegylated asparaginase (Courses 4, 6, and 8) to complete a total of 8 courses. Participants whose leukemia expresses CD20 will receive a total of 12 doses (2 per each of the first four courses, then one with the last four courses) of rituximab.

After the 8 courses, patients with lymphoblastic lymphoma who had enlarged lymph glands in the mediastinum may receive radiation to the chest. Those participants not needing radiation will proceed to monthly maintenance chemotherapy. This includes daily 6-mercaptopurine taken by mouth, weekly methotrexate by vein or mouth, monthly vincristine by vein, and dexamethasone by mouth for 5 days every month. Participants with lymphoblastic lymphoma will start maintenance chemotherapy after finishing radiation.

Maintenance chemotherapy will be given for a total of 30 months, and will be interrupted by 2 periods of intensive chemotherapy courses. The first will be at six months into the maintenance program starting first with hyper-CVAD (like Course 1) except without pegylated asparaginase). The following months, participants will receive methotrexate by vein on Day 1, vincristine by vein on Day 1, and pegylated asparaginase by vein on Day 2. Participants will receive this sequence of 2 chemotherapy courses again 18 months into the maintenance program. Participants with the CD20 marker will receive rituximab during the maintenance chemotherapy (with the vincristine during months 1, 3, 6, 7, 10, 13, 18 \& 19).

After one or two courses of therapy, the response to the treatment will be evaluated. If the leukemia or lymphoma is responding, the therapy will be continued. Participants will be taken off study if the leukemia or lymphoma starts to get worse.

After completion of treatment, participants will have a complete physical exam, including blood tests (about 8 teaspoons). If needed, a chest X-ray or CT scan will be done. A bone marrow sample will be taken through a large needle. Patients will then return every 3 to 6 months for a checkup, including blood tests and bone marrow aspiration. X-rays may be repeated if needed.

An Ommaya reservoir may also be placed surgically as a route to treat leukemia in the brain or to decrease the risk of leukemia in patients who have difficulty with the spinal treatments. An Ommaya reservoir is a tube inserted under the skin of the scalp that enters into the spinal fluid cavity of the brain.

Treatment will be given on an inpatient basis for the 8 intensive cycles of chemotherapy, or as indicated by the clinical condition. The maintenance treatments will be given as an outpatient but may be given as an inpatient if needed.

This is an investigational study. All of the drugs are commercially available. Their use together in this study is investigational. About 280 patients will take part in this study. All will be enrolled at M. D. Anderson Cancer Center.

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia

Response - Complete remission (CR): Normalization peripheral blood \& bone marrow 5% or \<blasts in normocellular or hypercellular marrow granulocyte count of 1x10\^9/L or \> \& platelet count \>100x10\^9/L; CR with incomplete platelet recovery (CRp): CR but platelet count \<100x10\^9/L. CR with incomplete recovery (CRi): CR but platelet count \<100x10\^9/L or absolute neutrophil count \< 1x10\^9/L. Partial response (PR): As above except for presence of 6-25% marrow blasts. Lymphoblastic lymphoma (\& ALL subtypes with extramedullary disease): CR - disappearance all known disease. PR - \>50% decrease in tumor size using sum of product, includes 50% volume decrease in lesions measurable in 3 dimensions. No Response (NR) - No significant change (includes stable disease). Lesions decreased size but \<50% or lesions with slight enlargement \<25% increase in size. Progressive Disease (PD): Appearance new lesions, 25% or \> increase in size existing lesions (\>50% if 1 lesion \& \<2).

M.D. Anderson Cancer Center

Rituximab 375 mg/m\^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m\^2 IV, Doxorubicin 50 mg/m\^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m\^2 IV followed by 800 mg/m\^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m\^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m\^2 a day IV, Pegylated asparaginase 2000 International units/m\^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hours after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.

HYPER-CVAD

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

Hagop Kantarjian, MD./ Chair

Complete Response (CR)

Complete Response without Platelet Recovery

Partial Response (PR)

Number of Participants With a Response

Overall Study

Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.

300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of

2 mg by vein (IV) weekly for 3: Days 1, 8, 15

80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18

Decadron

10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours

200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1

3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.

Ara-C

2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses

Stefan F. Faderl, M.D.

The goal of this clinical research study is to learn if a special combination of chemotherapy drugs called "augmented hyper-CVAD chemotherapy" given over 6 to 8 months followed by monthly maintenance chemotherapy for one year can help to control acute lymphoblastic leukemia or lymphoblastic lymphoma. The safety of this therapy will also be studied.

The augmented hyper-CVAD chemotherapy is a combination of chemotherapy drugs including cyclophosphamide, vincristine, adriamycin, dexamethasone, and pegaspargase given together for one "course" of treatment. It is called "augmented" because additional drugs are being added to the hyper-CVAD combination, which is the standard combination of chemotherapy drugs for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma. This switches back and forth with a course of the chemotherapy drugs methotrexate and ara-C (also with vincristine, dexamethasone, and pegaspargase).

Before treatment starts, you will have a physical exam, including blood (about 8 teaspoons) tests. You will also have a bone marrow sample taken; the sample will be taken through a large needle in the hipbone.

All participants will receive 2 kinds of chemotherapy courses for a total of 8 courses. Chemotherapy courses will be given through a large vein by a central venous catheter (a plastic tube usually placed under the collarbone).

During treatment, you will have a physical exam and give blood samples (about 1 tablespoon each) at least twice a week. A bone marrow sample will be repeated 2-3 weeks after the start of treatment to check the response, and later as needed.

Course 1 will include cyclophosphamide given by vein over 2-3 hours every 12 hours. This will be given for 6 doses over 3 days (Days 1, 2 and 3). Adriamycin will be given by vein over 24 hours on Day 4. Vincristine will be given by vein over 15 to 30 minutes on Days 1, 8, and 15. Dexamethasone (a steroid) will be given by mouth or by vein on Days 1 to 4 and 15-18. Pegaspargase will be given by vein over 1-2 hours on Day 1.

G-CSF (growth colony stimulating factor) will be given starting 24 hours after each course of chemotherapy is finished (Day 5 or 6). It is given to help with rapid recovery of the normal bone marrow. G-CSF will be injected by vein or under the skin until the blood counts recover.

Treatment to the brain will be given inside the spinal fluid (spinal tap) with ara-C and methotrexate on Days 2 and 7 of Courses 1 and 2 for a total of 4 treatments. This is done to decrease the risk that the leukemia will develop there.

During Course 2, you will receive methotrexate by infusion over 24 hours on the first day and ara-C by vein at a high dose over 2 hours every 12 hours for 4 doses (Days 2 and 3). You will also receive vincristine (Days 1, 8, and 15), dexamethasone (Days 1-4 and 15-18), and pegaspargase (Day 5).

Citrovorum factor (leucovorin), an antidote for side effects of methotrexate, will be given by vein or by mouth for 2-3 days (Day 2 and on). G-CSF will be given as in Course 1 (24 hours after the chemotherapy is finished). The treatment to the brain inside the spinal fluid will be given as in Course 1 on Days 2 and 7.

The schedule of chemotherapy will switch between hyper-CVAD (Courses 3, 5, and 7) and methotrexate/ara-C (Courses 4, 6 and 8) to complete a total of 8 courses. After the 8 courses, you will go on maintenance chemotherapy. This includes daily 6-mercaptopurine taken by mouth, weekly methotrexate by vein or mouth, monthly vincristine by vein, and prednisone by mouth for 5 days every month. Maintenance therapy will continue for one year.

Treatment will be given on an inpatient or outpatient basis for the 8 intensive courses of chemotherapy, as indicated by your condition. The maintenance treatments may be given as an outpatient. Patients will be taken off study if the disease gets worse or if intolerable side effects occur.

This is an investigational study. All of the drugs are commercially available. Their use together in this study is investigational. About 90 patients will take part in this study. All will be enrolled at UT MD Anderson Cancer Center.

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Phase II Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Complete remission (CR) required a marrow with ≤ 5% blasts in a normo- or hypercellular marrow with an absolute neutrophil count (ANC) of ≥ 1 \* 10\^9/L and a platelet count of ≥ 100 \* 10\^9/L with complete resolution of all sites of extramedullary disease required.

Enzon Pharmaceuticals, Inc.

Augmented Hyper-CVAD

Age Continuous

Stefan Fader, M.D./Associate Professor

Number of Participants With Complete Remission

Respiratory Tract (Lung and Bronchial) Diseases

Small Cell Lung Carcinoma

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Small Cell Lung Cancer

Topotecan

Topoisomerase I Inhibitors

CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))

Lurbinectedin (PM01183)

Doxorubicin (DOX)

Vincristine (VCR)

Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of an experimental arm consisting of PM01183/DOX combination followed by PM01183 alone, if applicable vs. best Investigator's choice between CAV or topotecan as a control arm, in SCLC patients who failed one prior platinum-containing line but no more than one prior chemotherapy-containing line.

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.

CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.

CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.

CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

PharmaMar

21 of 613 randomized patients did not receive the study treatment. Safety population consisted of 592 treated patients. 302 had been randomized to lurbinectedin/DOX and 290 to topotecan or CAV. However, one patient randomized to receive topotecan was treated with lurbinectedin/DOX instead. For safety data analysis, this patient has been moved to the lurbinectedin/DOX Arm, and the safety population thereby comprised 303 patients with lurbinectedin/DOX and 289 patients with topotecan or CAV.

Doxorubicin: 40.0 mg/m2 i.v. on Day 1 through peripheral or central lines (according to local label), followed by, Lurbinectedin: 2.0 mg/m2 i.v. as a 1-hour infusion on Day 1 q3wk (three weeks ±48h = one treatment cycle) through peripheral or central lines. A minimum volume of 100 mL diluted in 5% glucose or 0.9% sodium chloride solution for infusion, had to be used for administration through a central venous catheter; if a peripheral venous catheter was used, the minimum volume was 250 mL.

The combination was to be administered for up to a maximum of ten cycles.

Lurbinectedin/Doxorubicin

If the patient was randomized to the Control Arm, the assigned treatment was based on the reported Investigator's preference between topotecan and CAV, until the first of these options had reached 55% of the target patient enrollment in this arm. Once this had occurred, patients in the Control Arm were to receive the other option.

Topotecan: i.v. daily on Days 1-5 q3wk (three weeks ±48h = one treatment cycle) through peripheral or central lines (according to local label) at the following doses:

* 1.50 mg/m2 daily, for patients with calculated CrCL ≥60 mL/min.
* 1.25 mg/m2 daily, for patients with calculated CrCL between 40 and 59 mL/min.
* 0.75 mg/m2 daily, for patients with calculated CrCL between 30 and 39 mL/min.

If the patient was randomized to the Control Arm, the assigned treatment was based on the reported Investigator's preference between topotecan and CAV, until the first of these options had reached 55% of the target patient enrollment in this arm. Once this had occurred, patients in the Control Arm were to receive the other option.

CAV: i.v. on Day 1 q3wk (three weeks ±48h = one treatment cycle) through peripheral or central lines at the following doses:

* Cyclophosphamide: 1000 mg/m2,
* Doxorubicin: 45.0 mg/m2,
* Vincristine: 2.0 mg FD. The triple combination was to be administered for up to a maximum of ten cycles

Cyclophosphamide/Doxorubicin/Vincristine

If the patient was randomized to the Control Arm, the assigned treatment was based on the reported Investigator's preference between topotecan and CAV, until the first of these options had reached 55% of the target patient enrollment in this arm. Once this had occurred, patients in the Control Arm were to receive the other option.

Topotecan: i.v. daily on Days 1-5 q3wk (three weeks ±48h = one treatment cycle) through peripheral or central lines (according to local label) at the following doses:

* 1.50 mg/m2 daily, for patients with calculated CrCL ≥60 mL/min.
* 1.25 mg/m2 daily, for patients with calculated CrCL between 40 and 59 mL/min.
* 0.75 mg/m2 daily, for patients with calculated CrCL between 30 and 39 mL/min.

or

CAV: i.v. on Day 1 q3wk (three weeks ±48h = one treatment cycle) through peripheral or central lines at the following doses:

* Cyclophosphamide: 1000 mg/m2,
* Doxorubicin: 45.0 mg/m2,
* Vincristine: 2.0 mg flat dose. The triple combination was to be administered for up to a maximum of ten cycles

Topotecan or Cyclophosphamide/Doxorubicin/Vincristine

Total

Age, Customized

Race/Ethnicity, Customized

Argentina

Romania

Hungary

Czechia

United Kingdom

Portugal

Spain

Greece

Lebanon

Canada

Austria

Netherlands

Belgium

Brazil

Poland

Italy

Bulgaria

France

Germany

Weight

Height

Body surface area

Body mass index

Eastern Cooperative Oncology Group Performance Status (ECOG PS) PS 0 Fully active able to carry on all pre-disease performance without restriction PS 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature PS 2 Ambulatory and capable of all selfcare but unable to carry out any work activities up and about more than 50% of waking hours PS 3 Capable of only limited selfcare confined to bed or chair more than 50% of waking hours PS 4 Completely disabled cannot carry on any selfcare; totally confined to bed or chair PS 5 Dead

Eastern Cooperative Oncology Group Performance Status

Smoking status

Time from first diagnosis to randomization

Limited stage. Limited stage means that the cancer is only in 1 part of the chest and radiation therapy could be a treatment option.

Extensive stage. Extensive stage is used to describe SCLC that has spread to other parts of the body such as the opposite lung, bone, brain, or bone marrow.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia	NCT00671658	Leukemia Acute Lymphobla...	Rituximab Cyclophosphamid... Doxorubicin Vincristine Dexamethasone Methotrexate (M... Cytarabine G-CSF Mesna Pegylated aspar... Pegfilgrastim Solumedrol	-	M.D. Anderson Cancer Center
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia	NCT00671658	Leukemia Acute Lymphobla...	Rituximab Cyclophosphamid... Doxorubicin Vincristine Dexamethasone Methotrexate (M... Cytarabine G-CSF Mesna Pegylated aspar... Pegfilgrastim Solumedrol	-	M.D. Anderson Cancer Center
Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage	NCT00890656	Acute Lymphobla...	Cyclophosphamid... Vincristine Doxorubicin Decadron G-CSF Methotrexate (M... Ara-C Pegaspargase	-	M.D. Anderson Cancer Center
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer	NCT02566993	Small-cell Lung...	Lurbinectedin (... Doxorubicin (DO... Cyclophosphamid... Vincristine (VC... Topotecan	18 Years -	PharmaMar
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer	NCT02566993	Small-cell Lung...	Lurbinectedin (... Doxorubicin (DO... Cyclophosphamid... Vincristine (VC... Topotecan	18 Years -	PharmaMar
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer	NCT00002836	Breast Cancer	Filgrastim (G-C... Carmustine Cisplatin Cyclophosphamid... Etoposide Thiotepa Peripheral Bloo...	18 Years - 65 Years	M.D. Anderson Cancer Center
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)	NCT03396575	Diffuse Intrins... Brain Stem Glio...	TTRNA-DC vaccin... TTRNA-xALT Cyclophosphamid... Dose-Intensifie... Td vaccine Autologous Hema...	3 Years - 30 Years	University of Florida
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer	NCT00002836	Breast Cancer	Filgrastim (G-C... Carmustine Cisplatin Cyclophosphamid... Etoposide Thiotepa Peripheral Bloo...	18 Years - 65 Years	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for cyclophosphamide (ctx)